Mena FN

Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key Companies, MOA, ROA, And Clinical Trials Evaluation By Delveinsight Fulcrum Therapeutics, Dyne Therapeutics, GSK ...

(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Facioscapulohumeral Muscular Dystrophy pipeline constitutes 10+ key companies continuously working ...
equities

Fulcrum Therapeutics Raises $80 Million Series B Round for Facioscapulohumeral Muscular Dystrophy (FSHD)

Facioscapulohumeral muscular dystrophy (FSHD) is the most common of the nine primary types of muscular dystrophy. Studies once estimated prevalence to be about 1 in 20,000 people, according to the FSH ...
Mena FN

Facioscapulohumeral Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 10+ Companies Lead The Charge In Pioneering New Treatments Delveinsight

DelveInsight's“ Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in the Facioscapulohumeral Muscular ...